<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056247</url>
  </required_header>
  <id_info>
    <org_study_id>OH-HRPP-001</org_study_id>
    <nct_id>NCT04056247</nct_id>
  </id_info>
  <brief_title>Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments</brief_title>
  <acronym>PROPHETIC</acronym>
  <official_title>PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoHost Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OncoHost Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma&#xD;
      who could benefit from cancer treatment they receive.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this research study is to develop an algorithm that predicts the patient's&#xD;
      treatment outcome.This algorithm will serve as a tool for physicians when making treatment&#xD;
      decisions, specifically for stage IV NSCLC and malignant melanoma patients receiving&#xD;
      anti-cancer treatments. The investigators also aim to identify the metabolic pathways that&#xD;
      could lead to better therapeutic options. The patients will be given their treatment&#xD;
      according to the institute's standard of care. The patients will provide two blood samples&#xD;
      and clinical data will be collected from their medical records.&#xD;
&#xD;
      In the first part of the trial, the data obtained from the blood samples and the medical&#xD;
      records of the patients will be used to develop the prediction algorithm, and in the second&#xD;
      part of the trial, the algorithm will be validated by comparing the objective response rate&#xD;
      of the patients to the theoretical response prediction of the algorithm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) at 3 months</measure>
    <time_frame>At 3 months after therapy</time_frame>
    <description>ORR as defined by RECIST 1.1 or other validated method for ORR evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) at 6 months</measure>
    <time_frame>At 6 months after therapy</time_frame>
    <description>ORR as defined by RECIST 1.1 or other validated method for ORR evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the blood levels of different proteins that represent the host response</measure>
    <time_frame>At baseline (pre-therapy) and after 1st dose administration (post therapy)</time_frame>
    <description>Changes in Blood levels of proteins representing the Host response</description>
  </primary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>At second blood collection, 3 months and 6 months after treatment and EOS (2 years)</time_frame>
    <description>AE, as reported by the patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>At End of study (2 years)</time_frame>
    <description>Collect Progression Free Survival (PFS) dates</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>At End of study (2 years)</time_frame>
    <description>Collect Overall Survival (OS) dates</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>At End of study (2 years)</time_frame>
    <description>Collect Duration of Response (DOR) dates</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Malignant Melanoma of Uvea</condition>
  <condition>Stage IV Small Cell Lung Cancer</condition>
  <condition>Stage III Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed NSCLC stage IV</arm_group_label>
    <description>Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NSCLC stage IV 2nd line and further of immunotherapy</arm_group_label>
    <description>Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive lines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant melanoma stage IV</arm_group_label>
    <description>Patients with stage IV malignant melanoma treated with Immunotherapy with or without targeted therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malignant melanoma stage IIIb-d</arm_group_label>
    <description>Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SCLC stage IV</arm_group_label>
    <description>Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy + Chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Plasma sample collection</intervention_name>
    <description>Collect at least two plasma samples</description>
    <arm_group_label>Malignant melanoma stage IIIb-d</arm_group_label>
    <arm_group_label>Malignant melanoma stage IV</arm_group_label>
    <arm_group_label>NSCLC stage IV 2nd line and further of immunotherapy</arm_group_label>
    <arm_group_label>Newly diagnosed NSCLC stage IV</arm_group_label>
    <arm_group_label>SCLC stage IV</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma samples.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1. Patients with newly diagnosed stage IV NSCLC treated with Immunotherapy or&#xD;
             Immunotherapy + Chemotherapy.&#xD;
&#xD;
          2. Patients with NSCLC stage IV treated with Immunotherapy at 2nd line or consecutive&#xD;
             lines.&#xD;
&#xD;
          3. Patients with stage IV malignant melanoma treated with Immunotherapy with or without&#xD;
             targeted therapy.&#xD;
&#xD;
          4. Patients with stage IIIb-d malignant melanoma treated with Immunotherapy as adjuvant&#xD;
             therapy.&#xD;
&#xD;
          5. Patients with stage IV SCLC treated with Immunotherapy or Immunotherapy +&#xD;
             Chemotherapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cancer patients with stage IV NSCLC or stage IV malignant melanoma&#xD;
&#xD;
          -  Patient must have at least one measurable lesion and the relevant images in order to&#xD;
             enable assessment of response&#xD;
&#xD;
          -  ECOG PS - 0/1-2&#xD;
&#xD;
          -  Normal hematologic, renal and liver function:&#xD;
&#xD;
               1. Absolute neutrophil count higher than 1500/mm3&#xD;
&#xD;
               2. Platelets count higher than 100,000/mm3&#xD;
&#xD;
               3. haemoglobin higher than 9 g/dL&#xD;
&#xD;
               4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40&#xD;
                  mL/min&#xD;
&#xD;
               5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the&#xD;
                  upper normal limit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent and/or other active malignancy that has required systemic treatment within&#xD;
             2 years of first dose of study drug&#xD;
&#xD;
          -  Generalized impairment or mental incompetence that would render the patient unable to&#xD;
             understand his/her participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mor Moskovitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>003 Rambam Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michal Lotem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>001 Hadassah Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jair Bar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>006 Sheba Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maya Gottfried, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>005 Meir Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abed Agbaria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>004 Bnai Zion Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ido Wolf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>002 Tel Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmud Abu-Amana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>007 Haemek Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rivka Katsenelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>008 Kaplan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Yakobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>009 Soroka Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Harkovsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>011 Barzilai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ofer Rotem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>012 Rabin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ella Tepper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>013 Assuta Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raya Leibowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>014 Shamir Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Berger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>030 Rutgers Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Lutzky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>032 University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antony Magliocco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>015 Protean Biodiagnostics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gillian Price, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>020 Aberdeen Royal Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Cheley</last_name>
    <role>Principal Investigator</role>
    <affiliation>021 Swansea Bay UHB - Cancer Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Louise Medley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>022 Torbay and South Devon NHS foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tom Geldart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>023 Royal Bournemouth General Hospital Dorset</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anirban Chatterjee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>024 The Shrewsbury and Telford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Farrugia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>025 Cheltenham General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Polychronis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>026 Mount Vernon Cancer Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Polychronis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>027 Lister Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ari VanderWalde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>031 West Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davika Das, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>033 VAHCS Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alison Brewster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>051 Withybush Hospital Hawl Dda University Health Board</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Hassani</last_name>
    <role>Principal Investigator</role>
    <affiliation>029 Sunderland Royal Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam Hassani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>028 South Tyneside District</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Conn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>050 Bradford Teaching Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yanyan Lou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>034 Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galit Yahalom, Ph.D.</last_name>
    <phone>97248537554</phone>
    <email>galit@oncohost.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shani Raveh, Ph.D.</last_name>
    <phone>97248537554</phone>
    <email>shani@oncohost.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Birmingham VAHCS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davika Das, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanyan Lou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yanyan Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Protean Biodiagnosics</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Magliocco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Magliocco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Community Healthcare</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Hyeon Park</last_name>
      <email>sohyeon.park@proteanbiodx.com</email>
    </contact>
    <contact_backup>
      <last_name>Marina Messinger</last_name>
      <phone>8476184358</phone>
    </contact_backup>
    <investigator>
      <last_name>Marina Messinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen Nassif Community Cancer Center</name>
      <address>
        <city>Cedar Rapids</city>
        <state>Iowa</state>
        <zip>52403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Hyeon Park</last_name>
      <email>sohyeon.park@proteanbiodx.com</email>
    </contact>
    <contact_backup>
      <last_name>William Fusselman, MD</last_name>
      <phone>3193697775</phone>
    </contact_backup>
    <investigator>
      <last_name>William Fusselman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Berger, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adam Berger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari VanderWalde, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christus Health St. Michael</name>
      <address>
        <city>Texarkana</city>
        <state>Texas</state>
        <zip>75503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So Hyeon Park</last_name>
      <email>sohyeon.park@proteanbiodx.com</email>
    </contact>
    <investigator>
      <last_name>Hesham Hazin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Cetner</name>
      <address>
        <city>Tel Aviv</city>
        <state>HaMerkaz</state>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Tepper, MD</last_name>
      <phone>972-525282726</phone>
      <email>ellat@assuta.co.il</email>
    </contact>
    <investigator>
      <last_name>Ella Tepper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmud Abu-Amana, MD</last_name>
      <phone>972-4-6495686</phone>
      <email>mahmud_ab@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Mahmud Abu-Amana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gil Bar-Sela, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kamel Mahmid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Vornicova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noam Asna, Md</last_name>
      <phone>972-8-6745378</phone>
      <email>noama@barzi.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Noam Asna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Charkovsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moshe Schaffer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Yakobson, MD</last_name>
      <email>Alexy@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alexander Yakobson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shamir Medical Center</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raya Leibowitz-Amit, MD</last_name>
      <phone>972-8-9779715</phone>
      <email>rayal@shamir.gov.il</email>
    </contact>
    <investigator>
      <last_name>Raya Leibowitz-Amit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nirit Yarom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Nisimov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Svetlana Kovel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnold Cyjon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adi Rasco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abed Agbaria, MD</last_name>
      <phone>972-4835-9016</phone>
      <email>abed.agbarya@b-zion.org.il</email>
    </contact>
    <investigator>
      <last_name>Abed Agbaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ella Kozliner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yelena Shechtman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mor, MD</last_name>
      <phone>9724-7776700</phone>
      <email>m_moskovitz@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Mor Moskovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mira Wollner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahamoud Abu Amna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Talia Shentzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medcial Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Lotem, Prof.</last_name>
      <phone>972-2677-6781</phone>
      <email>mlotem@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Michal Lotem, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hovav Hovav Nechushtan, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Cohen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yakir Rottenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avner Mordechay, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meir medical center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Gottfried, MD</last_name>
      <phone>972-9747-2414</phone>
      <email>Maya.Gottfried@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Maya Gottfried, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natalie Maimon-Rabinovich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Moshe Mishaly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alona Zer, MD</last_name>
      <phone>972-39378146</phone>
      <email>Alonaz@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Alona Zer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hendler Daniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Reẖovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rivka Katsenelson, MD</last_name>
      <phone>972-89441087</phone>
      <email>Rivka_K@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Rivka Katsenelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Cetner</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Tepper, MD</last_name>
      <phone>972-3-7896541</phone>
      <email>ellat@assuta.co.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ido Wolf, Prof.</last_name>
      <phone>972-36925623</phone>
      <email>idow@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ido Wolf, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MOR MIODOVNIK, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ARI RAPHAEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>OFER MERIMSKY, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SHULIM SHPIGEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FREDERIC SINAI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HAGAI LIGUMSKY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba medical center</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jair Bar, MD</last_name>
      <phone>972-3530-7096</phone>
      <email>Yair.Bar@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Jair Bar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amir Onn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sameh Daher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Akram Saad, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shirley Grinberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ronen Shtoff, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Smadar Bauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamar Beller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Price, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gillian Price</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth General Hospital</name>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tom Geldart, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tom Geldart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Conn, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheltenham General Hospital</name>
      <address>
        <city>Cheltenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Farrugia, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Farrugia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Withybush Hospital</name>
      <address>
        <city>Haverfordwest</city>
        <zip>SA61 2PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison Brewster, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre</name>
      <address>
        <city>Northwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Polychronis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Polychronis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Shrewsbury and Telford Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anirban Chatterjee, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anirban Chatterjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Tyneside</name>
      <address>
        <city>South Shields</city>
        <zip>NE34 0PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Hassani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lister Hospital</name>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Polychronis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Polychronis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Hassani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swansea Bay UHB Singleton Hospital</name>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Cheley</last_name>
    </contact>
    <investigator>
      <last_name>Helen Cheley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Medley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Louise Medley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shaked Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat Rev Clin Oncol. 2016 Oct;13(10):611-26. doi: 10.1038/nrclinonc.2016.57. Epub 2016 Apr 26. Review.</citation>
    <PMID>27118493</PMID>
  </reference>
  <reference>
    <citation>Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res. 2007 Aug 1;67(15):7055-8. Review.</citation>
    <PMID>17671170</PMID>
  </reference>
  <reference>
    <citation>Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Curr Cancer Drug Targets. 2005 Nov;5(7):551-9. Review.</citation>
    <PMID>16305351</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 11, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

